Quantcast

Latest Paclitaxel Stories

2014-09-05 08:24:05

SAN DIEGO, Sept. 5, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, is scheduled to present a corporate overview at two upcoming conferences. Event: 16(th) Annual Rodman & Renshaw Global Investment Conference When: Tuesday, September 9, 2014 at 11:40 AM ET - 12:05...

2014-09-03 16:29:18

In the news release, Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study, issued 03-Sep-2014 by Oncolytics Biotech Inc. over CNW, we are advised by the company that at the end of the fourth paragraph, "150 patients" should read "110 patients". The complete, corrected release follows: Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study CALGARY,...

2014-09-03 08:32:29

CALGARY, Sept. 3, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN(®) versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study chair is David E. Cohn, MD, gynecologic oncology division director at The Ohio State University Comprehensive Cancer Center -...

2014-08-06 08:31:45

High unmet need addressed with first new approved treatment in eighteen years MISSISSAUGA, ON, August 6, 2014 /CNW/ - Health Canada has approved (Pr)ABRAXANE(®) for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab(®)] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer. The approval is welcome news for Canadians who are diagnosed with metastatic pancreatic cancer, and represents the first...

2014-07-31 20:23:05

SAN DIEGO, July 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) today announced the death of Mr. Amar Singh, Chief Business Officer and Executive Vice President. Mr. Singh died suddenly and unexpectedly of apparent natural causes on July 30. "Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Amar's family and friends," said Henry Ji, Ph.D., Sorrento's President and Chief Executive Officer....

2014-07-24 12:27:55

BUFFALO, N.Y., July 24, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months. KX2-391 is a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization. KX2-391 promotes the induction of p53, G2/M arrest...

2014-07-23 16:28:13

Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease MARLBOROUGH, Mass., July 23, 2014 /PRNewswire/ -- Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent(TM) Paclitaxel-Coated PTCA Balloon Catheter. The Agent Drug-Coated Balloon (DCB) provides physicians with an...

2014-07-22 08:32:36

Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant...

2014-07-15 08:28:12

HARBIN, China, July 15, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced the appointment of Tong Liu and Hengjiang (Henry) Pang to the Company's Board of Directors, effective August 1, 2014. "Tong and Henry are both excellent additions to our Board, with strong cross...

2014-07-14 08:27:37

Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger(TM) Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Ranger Drug-Coated Balloon (DCB)...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related